Experiment Number: S0305_2
Route: Gavage, IV
Species/Strain: Mouse/CD-1

Toxicokinetics Data Summary
Test Compound: 3'-Azido-3'-deoxythymidine
CAS Number: 30516-87-1

Date Report Requested: 01/11/2017
Time Report Requested: 12:23:24
Lab: Research Triangle Institute

Female

	Treatment Groups (mg/kg)		
	400 [1]	**400 [2]**	**100 IV [3]**
	Plasma		
C_{max} (ug/mL)	240	268	
k_{10} (minute^-1)	0.0200	0.0175	0.0283
$t_{1/2(k10)}$ (minute)	34.62	39.52	24.51
V_1 (mL/g)	0.699	0.795	0.499
AUC_{inf} (percent of dose*g*min/mL)	4298	5595	7080
F (percent of iv value)	60.7	79.0	100

LEGEND

Data are displayed as mean values

MODELING METHOD & BEST FIT MODEL

ADAPT II, a pharmacokinetic modeling package; 1-compartment, mono-exponential model

ANALYTE

3'-Azido-3'-deoxythymidine

DOSING

[1] 400 mg/kg of 3'-Azido-3'-deoxythymidine administered twice daily for 10 days, followed by a single time-interval exposure on day 11 (total of 21 doses)

[2] 400 mg/kg of 3'-Azido-3'-deoxythymidine administered once per study

[3] 100 mg/kg of 3'-Azido-3'-deoxythymidine administered once per study

TK PARAMETERS

C_{max} = Observed or Predicted Maximum plasma (or tissue) concentration

k_{10} = Elimination rate constant from the central compartment also k_e or k_{elim}

$t_{1/2(k10)}$ = Half-life for the elimination process from the central compartment

V_1 = Volume of distribution of the central compartment, includes V_d and V_{volume} of distribution, V_z apparent volume of distribution NCA, V_{app} apparent volume of distribution for intravenous studies

AUC_{inf} = Area under the plasma concentration versus time curve, AUC, extrapolated to time equals infinity

F = Bioavailability, absolute bioavailability

** END OF REPORT **